We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+51.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$361M
AUM Growth
+$93.2M
Cap. Flow
+$8.94M
Cap. Flow %
2.48%
Top 10 Hldgs %
42.47%
Holding
67
New
20
Increased
17
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$9.16M
2
ASND icon
Ascendis Pharma A/S
ASND
+$8.32M
3
NVTA
Invitae Corporation
NVTA
+$7.76M
4
OCUL icon
Ocular Therapeutix
OCUL
+$7.64M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$24.5M
2
BPMC
Blueprint Medicines
BPMC
+$12.6M
3
AMRN
Amarin Corp
AMRN
+$10.9M
4
XNCR icon
Xencor
XNCR
+$6.51M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Miscellaneous 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
26
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.74M 1.59%
1,152,500
-237,500
-17% -$1.17M
DERM
27
DELISTED
Dermira, Inc.
DERM
$5.42M 1.5%
400,000
+325,000
+433% +$2.71M
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$5.12B
$5.37M 1.49%
200,000
+5,000
+3% +$117K
XOMA
29
DELISTED
Xoma
XOMA
$4.95M 1.37%
400,000
– –
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.89M 1.35%
+185,000
New +$4.38M
VKTX icon
31
Viking Therapeutics
VKTX
$3.95B
$4.82M 1.34%
485,000
-340,000
-41% -$2.85M
EIDX
32
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$4.69M 1.3%
200,000
+60,000
+43% +$963K
TVTX icon
33
Travere Therapeutics
TVTX
$6.36B
$4.64M 1.28%
+205,000
New +$4.53M
ABEO icon
34
Abeona Therapeutics
ABEO
$345M
$4.12M 1.14%
22,400
+4,400
+24% +$787K
TVRD
35
Tvardi Therapeutics
TVRD
$24M
$3.92M 1.09%
+5,556
New +$3.33M
ATXI
36
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$3.8M 1.05%
711
+270
+61% +$1.72M
AIMT
37
DELISTED
Aimmune Therapeutics
AIMT
$3.69M 1.02%
165,000
+15,000
+10% +$353K
ACOR
38
DELISTED
Acorda Therapeutics
ACOR
$3.52M 0.98%
+2,208
New +$3.98M
SWAV
39
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$3.08M 0.85%
+92,100
New +$3.06M
FENC icon
40
Fennec Pharmaceuticals
FENC
$413M
$3.06M 0.85%
630,000
-270,000
-30% -$1.78M
CDTX
41
DELISTED
Cidara Therapeutics
CDTX
$2.65M 0.73%
50,000
-10,000
-17% -$548K
LQDA icon
42
Liquidia Corp
LQDA
$6.26B
$2.56M 0.71%
+225,000
New +$3.61M
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$2.24M 0.62%
115,000
-160,000
-58% -$2.52M
CMRX
44
DELISTED
Chimerix, Inc.
CMRX
$2.02M 0.56%
960,000
-1,060,000
-52% -$2.42M
CRNX icon
45
Crinetics Pharmaceuticals
CRNX
$9B
$1.66M 0.46%
+73,000
New +$1.79M
ESTA icon
46
Establishment Labs
ESTA
$2.14B
$1.2M 0.33%
+50,000
New +$1.33M
ZYME icon
47
Zymeworks
ZYME
$2.07B
$890K 0.25%
55,000
-50,000
-48% -$775K
THOR
48
DELISTED
Synthorx, Inc. Common Stock
THOR
$815K 0.23%
+40,000
New +$688K
FOMX
49
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$675K 0.19%
+180,000
New +$674K
KURA icon
50
Kura Oncology
KURA
$1.17B
$418K 0.12%
+25,200
New +$388K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opaleye Management held 67 positions worth $361M, up 35% from $268M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Opaleye Management's Q1 2019 filing shows 20 new, 17 increased, 12 reduced and 14 closed positions. Its largest new stake was uniQure: 205,000 shares worth $12.2M. The largest sale was Loxo Oncology, Inc, an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q1 2019 buy was uniQure: 205,000 shares worth $12.2M.
  • Opaleye Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2019, an estimated $4.83M increase.
  • Opaleye Management's biggest Q1 2019 reduction was Blueprint Medicines, cutting an estimated $12.6M.
  • Opaleye Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $24.5M.
  • Opaleye Management's ten largest holdings make up 42% of its $361M portfolio in Q1 2019.
  • Opaleye Management opened 20 new positions and closed 14 in Q1 2019.
  • Opaleye Management's portfolio value rose 35% quarter-over-quarter to $361M.

Based on Opaleye Management's 13F filing for Q1 2019, filed 15 May 2019.